Compare Natera Inc. Common Stock (NTRA) vs Zillow Group Inc Class C (Z) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Zillow Group Inc Class C — how do they compare? Natera Inc. Common Stock trades at $394.6 (market cap $57.03B), while Zillow Group Inc Class C trades at $28.41 (market cap $6.33B). The key difference: Natera Inc. Common Stock is far larger — about 9× Zillow Group Inc Class C's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Zillow Group Inc Class C nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Zillow Group Inc Class C for 39 Days on average.
| NTRA | Z | |
|---|---|---|
Market Cap | $57.03B | $6.33B |
Volume | 1,131,157 | 4,060,713 |
Sector | Health | Media |
52-Week High | $425.64 | $78.04 |
52-Week Low | $179.42 | $27.13 |
Typical Hold Time | 0 Days | 39 Days |
Enterprise Value | $56.18B | $6.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Zillow Group (Z) trades at $27.97, showing modest daily gains but facing bearish technical signals with the current price near key support levels. The company demonstrates improving fundamentals with revenue growth from $2.2B in 2024 to $2.6B in 2025 and a return to profitability, though valuation metrics remain elevated with a P/E of 121.57. Recent developments include AI integration initiatives and resolution of FTC litigation, while the housing market faces affordability challenges.
The stock presents a mixed outlook with analyst consensus pointing to significant upside potential (average target $52) but near-term headwinds from housing market volatility. Investment opportunity lies in Zillow's platform transition and market leadership, balanced against risks from mortgage rate sensitivity and competitive pressures. The current price near 52-week lows may offer entry points for long-term investors believing in the housing tech transformation story.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Zillow Group Inc Class C
Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →
